Journal article
Cumulative morbidity and prognostic staging of illness in the systematic treatment enhancement program for bipolar disorder (STEP-BD)
PV Magalhães, S Dodd, AA Nierenberg, M Berk
Australian and New Zealand Journal of Psychiatry | SAGE PUBLICATIONS LTD | Published : 2012
Abstract
Objective: Staging models may provide heuristic utility for intervention selection in psychiatry. Although a few proposals have been put forth, there is a need for empirical validation if they are to be adopted. Using data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), we tested a previously elaborated hypothesis on the utility of using the number of previous episodes as a relevant prognostic variable for staging in bipolar disorder. Methods: This report utilizes data from the multisite, prospective, open-label study Standard Care Pathways and the subset of patients with acute depressive episodes who participated in the randomized trial of adjunctive antide..
View full abstractGrants
Funding Acknowledgements
MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck and Servier.